Recently, Alberto Mantovani, a member of Henlius’ Scientific Advisory Board (SAB), Scientific Director and Emeritus Professor at Humanitas Clinical and Research Center in Italy, visited Henlius’ Shanghai Innovation Centre and shared insights and engaged in discussions regarding cutting-edge technologies and global innovation trends.

Prof. Mantovani is a renowned expert in the fields of immunology and inflammation, possessing extensive research experience. He has made significant contributions to the field of inflammation and its relationship with oncology. During the seminar, Prof. Mantovani delivered a presentation titled "Innate Immunity and Inflammation, from Cancer to COVID-19". Drawing from his research expertise and Henlius’ discovery research, he shared insights on the critical roles of immune and inflammatory mediators including macrophages, families of interleukin-1 (IL-1) and receptors (IL-1R) in disease progression, therapy and prevention. Moreover, he explained the intricate interconnections between innate immunity, inflammation, and the pathogenesis of various diseases, such as cancer and COVID-19, as well as strategies for systemic treatment. He then held an in-depth discussion with the attending scientists at Henlius.

Dr. Yongqiang Shan, general manager of Shanghai Innovation Centre, expressed gratitude to Prof. Mantovani for sharing his professional knowledge and insights during the seminar.  The collaboration with the members of the SAB, including Prof. Mantovani, will help the company in its research-and-development direction and will lead to more technological innovations. Henlius’ researchers benefitted from Prof. Mantovani's visit by engaging directly in a direct dialogue with one of the world's top minds, which enabled them to stay current with recent developments in the field. The collision of knowledge and ideas will greatly facilitate Henlius' further development of novel therapies and the realization of its vision to address unmet clinical needs.

Moving forward, Henlius will continue to foster dialogue with more global leading scientists, promote the translation of scientific achievements, accelerate the development of innovative therapies, and ultimately benefit more patients worldwide.